Navidea brings Lymphoseek to U.S. market

05/1/2013 | Wall Street Journal, The

Navidea Biopharmaceuticals is launching its lymphatic mapping radiopharmaceutical Lymphoseek in the U.S., the company announced today. Navidea has partnered with Cardinal Health to distribute the product to U.S. health care providers. "Commercialization of Lymphoseek in the U.S. marks a pivotal milestone for Navidea, and we are pleased to deliver this innovative diagnostic imaging agent to patients with breast cancer and melanoma," said Navidea President and CEO Dr. Mark Pykett. Lymphatic mapping helps trace the spread of cancer.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide